Skip Internal Navigation
The Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), formerly the Obstetric and Pediatric Pharmacology Branch (OPPB), promotes basic, translational, and clinical research to improve the safety and efficacy of therapeutics, primarily pharmaceuticals and to ensure centralization and coordination of research, clinical trials, and drug development activities for obstetric and pediatric populations.
The Branch is responsible for developing and supporting a comprehensive national effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, childhood, and adolescence using therapeutic approaches including medications that are appropriately tested within their target populations.
Implementation of the Best Pharmaceuticals for Children Act (BPCA) activities at the NICHD is among the major activities for the Branch.
- NEW! Slides from the Pre-Application Webinar for the Obstetric-Fetal Pharmacology Research Centers (OPRC) (PDF - 529 KB)
- Funding Opportunity Announcements:
- Translational Research in Pediatric and Obstetric Pharmacology (R01, R03, R21)
- Biomarkers: Bridging Pediatric and Adult Therapeutics (R01, R03, R21)
- Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01, R03, R21, R43, R41)
- Developmental Pharmacology and Toxicology: Role of Ontogeny (R01, R03, R21)
- Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01)
- Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children (R01)
- Safe and Effective Instruments and Devices for Use in Neonatal and Pediatric Care Settings (R41/42, R43/44)
- Obstetric-Fetal Pharmacology Research Centers OPRC (U54)
- Best Pharmaceuticals for Children Act (BPCA)